Business ❯ Healthcare ❯ Pharmaceuticals

Weight Loss Drugs

Novo Nordisk Eli Lilly Wegovy GLP-1 Drugs Market Competition Zepbound Eli Lilly Zepbound Viking Therapeutics GLP-1 Medications Clinical Trials Roche Compounded Semaglutide Mounjaro and Zepbound Compounded Drugs Tirzepatide Ozempic Orforglipron Compounded Medications GLP-1 Medicines Novo Nordisk A/S Telehealth Mounjaro GLP-1 Treatments

4 ARTICLES

4w ago

Lilly Pulls Ahead in GLP‑1 Market as Novo Confronts U.S. Headwinds

Investor bets plus Lilly's oral pill Foundayo, factory expansion, larger R&D outlays have created a wide valuation gap that leaves Novo's recovery dependent on its pipeline and global reach.

8 ARTICLES

5mo ago

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

6 ARTICLES

9mo ago

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength

Weight Loss Drugs

Lilly Pulls Ahead in GLP‑1 Market as Novo Confronts U.S. Headwinds

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Novo Nordisk Lifts Outlook After Wegovy Pill Fuels Q1 Beat

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Hims Launches $49 Compounded Wegovy-Style Pill as Novo Vows Legal Action

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength